Trial reportArchives of disease in childhood. Fetal and neonatal edition2023
Outcome at 4.5 years after dextrose gel treatment of hypoglycaemia: follow-up of the Sugar Babies randomised trial.
Trial report in Archives of disease in childhood. Fetal and neonatal edition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Mid-Childhood Outcomes after Dextrose Gel Treatment of Neonatal Hypoglycaemia: Follow-Up of the Sugar Babies Randomized Trial.Neonatology · 2023Trial
- Three is Better Than Two: Dose-related Efficacy of Dextrose Gel for Neonatal Hypoglycemia in At-Risk Infants, a Quality Improvement Initiative.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- Oral dextrose gel for hypoglycemia in a well-baby nursery: a baby-friendly initiative.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- Neonatal hypoglycaemia.BMJ medicine · 2024Review
- What are the barriers preventing the screening and management of neonatal hypoglycaemia in low-resource settings, and how can they be overcome?Maternal health, neonatology and perinatology · 2023Review
- Application of the screening test principles to screening for neonatal hypoglycemia.Frontiers in pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveDextrose gel is used to treat neonatal hypoglycaemia, but later effects are unknown. DESIGN AND
settingFollow-up of participants in a randomised trial recruited in a tertiary centre and assessed in a research clinic. PATIENTS: Children who were hypoglycaemic (<2.6 mmol/L) recruited to the Sugar Babies Study (
interventionsAssessment of neurological status, cognitive ability (Weschler Preschool and Primary Scale of Intelligence), executive function (five tasks), motor function (Movement Assessment Battery for Children-2 (MABC-2)), vision, visual processing (Beery-Buktenica Development Test of Visual Motor Integration (Beery VMI) and motion coherence thresholds) and growth at 2 years.
main outcome measuresNeurosensory impairment (cerebral palsy; visual impairment; deafness; intelligence quotient <85; Beery VMI <85; MABC-2 score <15th centile; low performance on executive function or motion coherence).
resultsOf 237 babies randomised, 185 (78%) were assessed; 96 randomised to dextrose and 89 to placebo gel. Neurosensory impairment was similar in both groups (dextrose 36/96 (38%) vs placebo 34/87 (39%), relative risk 0.96, 95% CI 0.66 to 1.34, p=0.83). Secondary outcomes were also similar, except children randomised to dextrose had worse visual processing scores (mean (SD) 94.5 (15.9) vs 99.8 (15.9), p=0.02) but no differences in the proportion with visual processing scores <85 or other visual test scores. Children randomised to dextrose gel were taller (z-scores 0.18 (0.97) vs -0.17 (1.01), p=0.001) and heavier (0.57 (1.07) vs 0.29 (0.92), p=0.01).
conclusionsTreatment of neonatal hypoglycaemia (<2.6 mol/L) with dextrose gel does not alter neurosensory impairment at 4.5 years. However, further assessment of visual processing and growth may be warranted. TRIAL REGISTRATION NUMBER: ACTRN1260800062392.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.